Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price dropped 4.6% on Tuesday . The company traded as low as $11.73 and last traded at $11.40. Approximately 3,361 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 6,249 shares. The stock had previously closed at $11.95.
Analysts Set New Price Targets
Several research firms have issued reports on PHAR. HC Wainwright restated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer increased their price objective on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.
Check Out Our Latest Stock Analysis on Pharming Group
Pharming Group Trading Down 6.0%
The firm's 50 day moving average is $9.57 and its 200 day moving average is $9.13. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The company has a market cap of $739.57 million, a PE ratio of -41.81 and a beta of 0.02.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million during the quarter, compared to analyst estimates of $67.74 million. On average, equities analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
